The role of platelet-activating factor in human fetal lung maturation

The presence of the potent bioactive glycerophospholipid 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) in a lamellar body-enriched fraction of amniotic fluid from women in labor has prompted the present investigation to examine the fetal lung as the possible tissue source of this platelet-activating factor. The metabolism of platelet-activating factor was assessed in an organ culture system in which human fetal lung tissue (12 to 16 weeks) was incubated for 6 to 7 days. During this period, the type II pneumonocytes differentiate and surfactant glycerophospholipid biosynthesis is greatly enhanced. The initial specific activity of the platelet-activating factor biosynthetic enzyme lyso-platelet-activating factor:acetyl-coenzyme A acetyltransferase is two to three times greater in microsomes prepared from fetal lung than in those from the fetal liver or kidney. The specific activity of acetyltransferase in lung tissue increased twofold after 6 days in organ culture. A similar increase in acetyltransferase activity was found in the lamellar body-enriched (18,000 X g) subcellular fraction of fetal lung. The activity of the major platelet-activating factor-inactivating enzyme platelet-activating factor acetylhydrolase did not change significantly in the lung explants during the incubation period. Associated with the enhanced platelet-activating factor biosynthetic activity in the fetal lung was an increase in the platelet-activating factor concentration, from 17 to 37 fmol/mg of protein between days 0 and 6 of culture. Corresponding increases of 3.3- and 3.8-fold in the concentrations of the platelet-activating factor lipid precursors lyso-platelet-activating factor and the 2-acyl congener were found after 6 days in culture. A reciprocal relationship was found between platelet-activating factor and glycogen content as the lung tissue matured in vitro; specifically, as the platelet-activating factor level increased, glycogen decreased from 340 to 77 micrograms/mg of protein. We suggest that platelet-activating factor may mediate the onset of glycogenolysis in fetal lung tissue similar to that in the isolated, perfused rat liver (Shukla SD, Buxton DB, Olson MS, Hanahan DJ. Acetylglyceryl ether phosphorylcholine. A potent activator of hepatic phosphoinositide metabolism and glycogenolysis. J Biol Chem 1983; 258:10212-4). The increased rate of glycogen degradation may serve as the carbon and energy source for the increased synthesis of glycerophospholipids required for surfactant production.(ABSTRACT TRUNCATED AT 400 WORDS)     

A generalised deficit can account for problems in facial emotion recognition in schizophrenia.

Neuroimaging research has shown localised brain activation to different facial expressions. This, along with the finding that schizophrenia patients perform poorly in their recognition of negative emotions, has raised the suggestion that patients display an emotion specific impairment. We propose that this asymmetry in performance reflects task difficulty gradations, rather than aberrant processing in neural pathways subserving recognition of specific emotions. A neural network model is presented, which classifies facial expressions on the basis of measurements derived from human faces. After training, the network showed an accuracy pattern closely resembling that of healthy subjects. Lesioning of the network led to an overall decrease in the network's discriminant capacity, with the greatest accuracy decrease to fear, disgust and anger stimuli. This implies that the differential pattern of impairment in schizophrenia patients can be explained without having to postulate impairment of specific processing modules for negative emotion recognition.     

Development of a bullous pemphigoid after split-skin grafting.

An elderly female patient developed blisters localised to her split-skin donor and graft sites. Despite repeated swabs, bacteriology and virology returned negative; multiple antibiotic courses did not improve her condition, which generalised within weeks. Histology and immunofluorescence confirmed a clinical diagnosis of bullous pemphigoid and her condition resolved rapidly after treatment with prednisolone. Bullous pemphigoid can be precipitated or exacerbated by surgery and the diagnosis should be considered when patients present with persistent localised or generalised blisters, especially when microbiological investigations are negative.     

ATRIAL NATRIURETIC FACTOR IN CHRONIC RENAL FAILURE: STUDIES IN MAN AND THE RAT

1. Plasma concentration and atrial content of atrial natriuretic factor (ANF) were measured in rats with chronic renal failure induced by subtotal nephrectomy. 2. Plasma ANF was higher, and atrial ANF content lower in rats with renal failure when compared with sham-operated controls. 3. Plasma renin activity (PRA) and ANF were elevated at 1 week following subtotal nephrectomy. After 1 month plasma ANF had risen further, but PRA was suppressed to below control values. 4. Plasma ANF was also measured in six patients with chronic renal failure undergoing routine haemodialysis. 5. Elevated plasma ANF levels in patients with renal failure were lowered by haemodialysis, although extraction of ANF across the dialysis membrane was negligible. 6. Secretion of ANF is increased in chronic renal failure in man and the rat, possibly mediated by increased intravascular volume.     

Effect of cell wall skeleton and monophosphoryl lipid A adjuvant on the immunogenicity of a murine B16 melanoma vaccine

We examined the effect of a new adjuvant consisting of purified mycobacterial cell wall skeleton (CWS) and monophosphoryl lipid A (MPL) on the immunogenicity of a murine melanoma vaccine. C57BL/6 mice were immunized to partially purified B16 melanoma vaccine given alone or together with different dose levels of adjuvant, or with saline or adjuvant alone. Humoral response, delayed-type hypersensitivity (DTH), in vitro cytotoxicity, and tumor-protective immunity to melanoma were measured following three biweekly immunizations. The adjuvant potentiated the antibody response to some, but not all, melanoma antigens in a dose-dependent fashion. The adjuvant also potentiated cellular immunity as measured by in vitro cytotoxicity assays. No potentiation of tumor-protective immunity was detected. In comparison to Freund's complete adjuvant, cell wall skeleton plus monophosphoryl lipid A (CWS:MPL) induced fewer cutaneous toxic effects and stronger antibody and DTH responses but resulted in no greater in vitro cytotoxicity or tumor-protective immunity. Thus, the adjuvant had a selective and dose-dependent effect on humoral responses to vaccine immunization but did not potentiate a tumor-protective immunity to B16 melanoma.     

STIMULATION OF PHOSPHATIDYLINOSITOL METABOLISM IN THE HEART

Receptor-stimulated hydrolysis of inositol phospholipids was studied in atrial and ventricular myocytes isolated from guinea-pigs. Acetylcholine and carbachol stimulated inositol phosphate accumulation with a maximum of more than 12 times the unstimulated values in atrial myocytes and 7 times in ventricular myocytes. The vasoactive peptides angiotensin II and vasopressin also stimulated inositol phosphate accumulation, but the maximum effect was lower than that mediated through muscarinic receptors. However, the adenosine analogues, L-N6-phenylisopropyladenosine and 5'N-ethylcarboxamidoadenosine which, like muscarinic agonists depress cardiac contractility, did not affect inositol phosphate accumulation at concentrations up to 10(-4) mol/l. Stimulation of phosphatidylinositol turnover in heart bears no obvious relationship to either contractility or release of atrial natriuretic factor.     

Fatal peptic ulcer complications and the use of non-steroidal anti-inflammatory drugs, aspirin, and corticosteroids

Although non-steroidal anti-inflammatory drugs are known to cause peptic ulcer and its complications, controversy exists about the number of deaths from ulcer which are attributable to their use. A case-control study was therefore performed to determine whether prior use of non-steroidal and other anti-inflammatory compounds was associated with an increased case fatality rate from complications of peptic ulcer. Non-steroidal anti-inflammatory drugs were used by 39% of a series of 80 patients who had died from peptic ulcer complications and by 37% of 160 controls who were survivors matched for sex, age, ulcer site, and nature of complication (odds ratio 1.1; 95% confidence interval 0.6 to 2.1). Similarly, the rates of prior use of aspirin by cases and controls were almost identical (odds ratio 1.2; 95% confidence interval 0.5 to 1.9). Thus neither nonsteroidal anti-inflammatory drugs nor aspirin were associated with increased case fatality rates from peptic ulcer complications. In contrast, corticosteroids were associated with an increased mortality (odds ratio 4.2; 95% confidence interval 0.9 to 25.6). Although this increase in the estimated relative risk was not statistically significant, a review of the case records indicated that most deaths in steroid users were due to serious sepsis, indicating that there might be a causal association between use of the drugs and the mode of death.